Abstract:HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.Tissue distributions profiles and plasma concentration–time curves in mice of 4r, 10m, and 19f; detailed experimental procedures for the synthesis of analogues 10a, 10b, 10i, 10j, 10k and intermediates 18h–18n; characterization (1H NMR spectra and 13C NMR spectra are attached) and HPLC purity control of the selected final compounds 10l, 10m, 18a, 18b, 18d, 18e, 18g, 19a–19h (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">PDF</a>)Molecular-formula strings of the reported compounds and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Development of anti-HBV agents targeting HBV capsid proteins

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Preclinical Characterization of a Novel Potent Core Protein Assembly Modulator for the Treatment of Chronic Hepatitis B Viral Infection

Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice

Discovery Of (1h-Pyrazolo[3,4-C]Pyridin-5-Yl)Sulfonamide Analogues As Hepatitis B Virus Capsid Assembly Modulators By Conformation Constraint

Rational Design, Synthesis, and Structure-Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836

An Aptamer Targets Hbv Core Protein And Suppresses Hbv Replication In Hepg2.2.15 Cells

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings

Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels